Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$84M Buy
+389,000
New +$74.4M 0.31% 61
2023
Q4
Sell
-92,500
Closed -$23.8M 1001
2023
Q3
$23.8M Buy
92,500
+67,500
+270% +$18.1M 0.27% 89
2023
Q2
$7.12M Buy
+25,000
New +$7.44M 0.08% 217
2022
Q4
Sell
-685,300
Closed -$183M 1120
2022
Q3
$183M Buy
+685,300
New +$146M 3.37% 1

Other funds holding BIIB

LMR Partners's BIIB Position: Q2 2026 in Review

LMR Partners reduced its Biogen (BIIB) stake by 96% in Q2 2026, selling an estimated $21.3M and leaving 4,866 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1041.

LMR Partners first reported a position in BIIB in Q2 2014 and has held it in 25 quarters since. The position peaked at $49.9M in Q2 2023. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • LMR Partners held 4,866 shares of Biogen worth $1.05M as of Q2 2026.
  • LMR Partners sold 111,265 Biogen shares in Q2 2026, an estimated $21.3M.
  • Biogen made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1041 holding.
  • LMR Partners first reported a position in Biogen in Q2 2014 and has held it in 25 quarters since.
  • LMR Partners's Biogen position peaked at $49.9M in Q2 2023.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.